Biiontech wants to further expand its Corona vaccine production and promote research in cancer therapy in the first three months in the first three months in the first three months. "Our goal is to become the global power center of immunotherapy in 21. Century", said board leader Uugur Sahin on Monday in the presentation of economic data in the first quarter.
The Mainz biotechnology company achieved a net profit of 1.1 billion euros in the first quarter of this year, as shown in a Communication from BionTech. Compared to the fourth quarter of 2020 (366.9 million euros), this means a tripling. In the first quarter of 2020, BIONTECH had to accept a net loss of 53 million euros – the main reason for this were high research and development costs.
Even more rapid rose sales, which reached 2.05 billion euros in the first three months after leading numbers. That was more than 70 times as much as in the corresponding period 2020 (27.7 million). The increase is mainly due to the rapid increase in global care with the Corona vaccine, exploited Financial Chef Sierk Petting in a web conference. Until 6. May, more than 450 million vaccine cans in 91 countries or regions were delivered worldwide. BIONTECH has joined for this purpose with the US Pharmases Pfizer.
Expansion of corona vaccine production
Biontech is aware of his global responsibility in the fight against the Corona Pandemic, said Sahin. Therefore, the production capacity for this year was increased by originally 1.3 billion vaccine doses to up to three billion. These are expected to be more than 40 percent for medium and low income countries, Sahin said, with a view to receivables, a globally equitable distribution of the vaccine and a lifting of patents.
BIONTECH will build a downright in Singapore and there also build a production facility for the mRNA vaccine, said Sahin. "Together with other vaccine developers, more than enough vaccine is produced in the next nine to twelve months, and there is no the least need to lift patents." For the effectiveness of the Corona vaccine Sahin said, the active substance is also effective against the previously encountered variants, so it is currently not necessary to adapt the vaccine.
MRNA method for cancer therapy
The BionTech boss Ozlem Tureci stated for medical research was confident that the company’s projects are promising to cancer therapies. In first clinical tests, it has been shown that active ingredients could reduce the size of tumors with mRNA messenger molecules.